These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38475901)

  • 1. Eyelash serums: A comprehensive review.
    Baiyasi M; St Claire K; Hengy M; Tur K; Fahs F; Potts G
    J Cosmet Dermatol; 2024 Jul; 23(7):2328-2344. PubMed ID: 38475901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.
    Steinsapir KD; Steinsapir SMG
    Dermatol Surg; 2021 May; 47(5):658-665. PubMed ID: 33625141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced eyelashes: prescription and over-the-counter options.
    Jones D
    Aesthetic Plast Surg; 2011 Feb; 35(1):116-21. PubMed ID: 20730536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse periocular reactions to five types of prostaglandin analogs.
    Inoue K; Shiokawa M; Higa R; Sugahara M; Soga T; Wakakura M; Tomita G
    Eye (Lond); 2012 Nov; 26(11):1465-72. PubMed ID: 23037910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and quantification of undeclared PGF
    Rahman MS; Yoshida N; Hanafusa M; Matsuo A; Zhu S; Stub Y; Takahashi C; Tsuboi H; Matsushita R; Maekawa K; Kimura K
    J Pharm Biomed Anal; 2022 Sep; 219():114940. PubMed ID: 35882176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimatoprost in the treatment of eyelash hypotrichosis.
    Law SK
    Clin Ophthalmol; 2010 Apr; 4():349-58. PubMed ID: 20463804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
    Harii K; Arase S; Tsuboi R; Weng E; Daniels S; VanDenburgh A
    Aesthetic Plast Surg; 2014 Apr; 38(2):451-60. PubMed ID: 24643895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
    Giannico AT; Lima L; Russ HH; Montiani-Ferreira F
    J Ocul Pharmacol Ther; 2013 Nov; 29(9):817-20. PubMed ID: 23981234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
    Esaki Y; Katsuta O; Kamio H; Noto T; Mano H; Iwamura R; Yoneda K; Odani-Kawabata N; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):529-533. PubMed ID: 32412835
    [No Abstract]   [Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study.
    Ricar J; Cetkovska P; Hordinsky M; Ricarova R
    Dermatol Ther; 2022 Jun; 35(6):e15438. PubMed ID: 35278027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hypotrichosis of the eyelashes: focus on bimatoprost.
    Fagien S
    Plast Surg Nurs; 2015; 35(2):82-91. PubMed ID: 26020474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
    Smith S; Fagien S; Whitcup SM; Ledon F; Somogyi C; Weng E; Beddingfield FC
    J Am Acad Dermatol; 2012 May; 66(5):801-6. PubMed ID: 21899919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface.
    Bitton E; Courey C; Giancola P; Diaconu V; Wise J; Wittich W
    Clin Exp Optom; 2017 Nov; 100(6):583-589. PubMed ID: 28122407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term utility and durability of the therapeutic effects of bimatoprost 0.03% for eyelash augmentation in healthy Asian subjects.
    Kwon O; Kim JY; Paik SH; Jeon HC; Jung YJ; Lee Y; Baek JH; Chun JH; Lee WS; Lee JY; Rogers JD; Halstead M; Eun HC
    Dermatology; 2014; 229(3):222-9. PubMed ID: 25228046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hypotrichosis of the eyelashes: Focus on bimatoprost.
    Fagien S
    Clin Cosmet Investig Dermatol; 2010 Apr; 3():39-48. PubMed ID: 21437058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.
    Yoshino T; Fukuchi T; Togano T; Seki M; Ikegaki H; Abe H
    Jpn J Ophthalmol; 2013 Mar; 57(2):172-8. PubMed ID: 23208023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
    Glaser DA; Hossain P; Perkins W; Griffiths T; Ahluwalia G; Weng E; Beddingfield FC
    Br J Dermatol; 2015; 172(5):1384-94. PubMed ID: 25296533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss?
    Jamison A; Okafor L; Ullrich K; Schiedler V; Malhotra R
    Aesthet Surg J; 2022 Oct; 42(11):1241-1249. PubMed ID: 35700523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
    Fagien S; Walt JG; Carruthers J; Cox SE; Wirta D; Weng E; Beddingfield FC
    Aesthet Surg J; 2013 Aug; 33(6):789-98. PubMed ID: 23873891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.